Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on STADA ARZNEIMITTEL AG. We currently have 8 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
STADA ARZNEIMITTEL AG
STADA ARZNEIMITTEL AG
Q3 16 : roughly in line, despite Russia and the UK
10 Nov 16
Stada reported Q3 16 figures. Sales reached €507m (-0.1%), EBITDA €88.4m (-11%, -6% adjusted), net income €18.3m (-50%, +4% adjusted). Over 9 months, sales totalled €1,541.7m (+0.5%), EBITDA €289.1m (+3%, +2% adjusted), and net income €100.3m (+11%, +10% adjusted). Net debt at the end of Q3 was €1,187m (vs €1,211.3m at the end of H1 and €1,216m at year-end 2015. The group targets an adjusted net income of “at least €180m” for FY16 (which compares to “a slight growth on FY15” previously, keeping in mind adjusted net income reached €165.8m last year).
H1 16: well on track for FY guidance
04 Aug 16
Revenues were up +1% to 1,037.4m, reported EBITDA +11% to €200.7m (adjusted +7%), operating income +22% to €136.3m (+11% adjusted) and net income +53% to 82m (+13% adjusted). Net debt reached €1,211.3m vs €1,216m at year-end 15. Management confirmed its outlook for FY16, according to which slight growth in sales adjusted for currency and portfolio effects, adjusted EBITDA and adjusted net income is to be expected. Looking further ahead, the group anticipates sales of €2.6bn, adjusted EBITDA of €510m and adjusted net income of €250m within a +/-5% range for FY19.
Q1 16: not too bad...
12 May 16
Q1 16 revenues were up 2% to €497.1m (+4% lfl at CER), EBITDA up 7% to €85.2m, adjusted EBITDA down 1% to €92.1m, operating profit up 12% to €56.3m (flat on an adjusted basis) and net income up 40% to €29.6m (+6% adjusted). The group maintains its guidance for the full-year, i.e. a slight growth in sales adjusted for currency and portfolio effects, adjusted EBITDA and adjusted net income.
FY15 in line. Russia still a worry for FY16
23 Mar 16
Stada released FY15 results. Sales reached €2,115.1m (+3% and +4% on a constant scope and currency basis), EBITDA €377.1m (-10%), adjusted EBITDA €389.4m (-10%), operating profit €223.7m (+19%) and adjusted operating profit €283.8m (-12%), net income €110.4m (+71%) and €165.8m (-11%) on an adjusted basis. Looking into FY16, the group anticipates a slight growth in sales adjusted for currency and portfolio effects, adjusted EBITDA and adjusted net income. Net debt reached €,1215.7m at year-end 2015. Lastly, the dividend proposed will be €0.70 (vs €0.66 last year).
Preliminary FY15: no reason to get excited
29 Feb 16
Stada released preliminary FY15 numbers. Sales are expected to have reached €2,115.1m (+4% at CER and constant scope), EBITDA €377.1m (-10%), adj. EBITDA €389.4m (-10%), net income €110m (+71%) and €165.8m (-11%) on an adjusted basis. The increase in reported net income (€110.4m vs €64.6m) is mainly attributable to far higher impairments in FY14. Net debt is expected at €1,215.7m. The dividend proposed will be €0.70 (after €0.66 in FY14).
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Morning Song 12-01-2017
12 Jan 17
As anticipated, the second half has again been stronger than H1 and results will be broadly in line with expectations. In line with this, the order book has continued to grow and is at record levels. This confirms that significant progress has been made in the Group’s shift towards its Technology Products division which, as targeted, contributed c.60% of group revenue in FY16. The small acquisition of Cable Power also gives a complementary boost to the product range. It is also worth noting the significant reduction in net debt, £1.0m ahead of our forecast. We remain supportive of the Group’s strategy and continue to see a bright future as this transition towards a design led technology solutions business continues. We look forward to more detail in March at the final results.
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Morning Song 16-01-2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.